1. In Vivo

Roche Teams With Spero To Target Gram-Negative Pathogens

Roche gets an option to acquire program addressing drug-resistant gram-negative infections when it reaches IND-filing status. Spero is working on a novel target found originally in infected tobacco plants.

Spero Therapeutics LLC, launched in 2013 with seed funding from Atlas Venture with a focus on developing novel antibiotics for gram-negative infections, has signed its first partner. The Cambridge, MA-based biotech announced April 9 that it will partner with Roche on preclinical development of a molecule addressing an undisclosed novel target that has shown the ability in preclinical studies to shut off the effects of gram-negative pathogens. [See Deal]

Roche is providing non-dilutive R&D funding to Spero, which is about halfway through the IND-enabling work for the candidate, said...

More from Business Strategy

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By Jo Shorthouse

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 
• By Anabel Costa-Ferreira

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.